
Translational oncology Ph.D. candidate with extensive training in cancer cell biology, cancer metabolism, photodynamic therapy (PDT), redox biology, live-cell imaging, and in vivo tumor models. My doctoral work focuses on developing and biologically validating cyanine-carborate organic salt photosensitizers as next-generation light-activated agents for tumor imaging and therapy. I have experience connecting therapeutic response with mechanism-of-action studies, biodistribution, oxidative stress signaling, targeted metabolite analysis, and resistance biology in metastatic breast cancer and head and neck squamous cell carcinoma models. My long-term goal is to bridge preclinical cancer biology with biomarker-driven therapeutic development and clinically relevant translational oncology.
Amir Roshanzadeh, et al. Cystine-dependent Redox Metabolism Determines Photodynamic Therapy Response in Head and Neck Squamous Cell Carcinoma
Patent: Carborate and Borohydride Salts (U.S. Filed, 2025).
Co-founder, Joule Therapeutics, Inc.; contributing to translational development of cyanine-carborane photosensitizer technology for cancer therapy applications.